Biora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 15, 2022 at 05:37 pm EDT
Share
Biora Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 0.104 million compared to USD 0.463 million a year ago. Net loss was USD 5.51 million compared to USD 78.53 million a year ago. Basic loss per share from continuing operations was USD 0.75 compared to USD 16.25 a year ago. Basic loss per share was USD 0.75 compared to USD 30.75 a year ago.
For the six months, sales was USD 0.211 million compared to USD 0.63 million a year ago. Net loss was USD 19.32 million compared to USD 110.8 million a year ago. Basic loss per share from continuing operations was USD 2.75 compared to USD 24.25 a year ago. Basic loss per share was USD 2.5 compared to USD 45.5 a year ago.
Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and needle-free delivery of biotherapeutics. The Company's therapeutics pipeline includes two therapeutic delivery platforms: NAVICAP and BIOJET. NAVICAP is a targeted oral delivery platform of therapeutics to the site of disease in the GI tract, designed to improve outcomes for patients with inflammatory bowel disease (IBD). The NAVICAP drug delivery device is an investigational, clinical-stage, single-use ingestible device approximately the size of a fish oil capsule. BIOJET is a systemic oral delivery platform of biotherapeutics designed to replace injection with needle-free, oral delivery of molecules for better management of chronic diseases. The Company's targeted therapeutics pipeline programs include NAVICAP, BT-600 and BT-001. Its systemic therapeutics pipeline programs include BIOJET, BT-200 and BT-002.